Product Description
Magnesium sulfate is a magnesium salt having sulfate as the counterion. It has a role as an anticonvulsant, a cardiovascular drug, a calcium channel blocker, an anaesthetic, a tocolytic agent, an anti-arrhythmia drug, an analgesic and a fertilizer. It is a magnesium salt, a metal sulfate and an organic magnesium salt. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Magnesium-sulfate)
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Croatia | Czech | Denmark | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Colocap Pharmaceuticals Pty Ltd
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Spain, Sweden
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Total Knee Arthroplasty
Phase 2: Back Pain|Pain, Postoperative
Phase 1: Injuries/wounds Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-519617-56-00 |
2024-519617-56-00 | P2 |
Not yet recruiting |
Pain, Postoperative |
2026-09-28 |
2025-05-02 |
Treatments |
|
NCT06393608 |
MP-04-2023-784 | P2 |
Recruiting |
Back Pain |
2025-12-15 |
2024-12-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
2024-518601-17-00 |
FPS-SMG-2021-02 | P3 |
Not yet recruiting |
Total Knee Arthroplasty |
2025-07-31 |
2025-05-02 |
Treatments |
|
CTR20233929 |
CTR20233929 | P1 |
Recruiting |
Injuries/wounds Unspecified |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/03/2026 |
News Article |
Global Magnesium Oxide Market to Reach USD 8.7 Billion by 2035 as Steel Modernization and Environmental Compliance Accelerate |
|
09/16/2025 |
News Article |
Novocuff Announces IDE Approval for the RETAIN Study |
|
08/25/2025 |
News Article |
Water for Injection Market Size to Surpass USD 87.39 Billion by 2034 Boosted by Growth in Gene and Cell Therapies |
|
07/17/2025 |
News Article |
Magnesium Sulfate Market Volume to Exceed 3,670.97 Thousand Tones by 2034 |